Our multivariate analysis underscores the critical need to incorporate routine NGS testing in managing NSCLC patients at the time of metastatic diagnosis, with particular emphasis on determining SMARCA4 mutation class in those with KRAS co-mutations. Here, KRAS is linked to non-small cell lung carcinoma.